6 Survival results of PSMA/PET-based salvage radiotherapy for recurrent prostate cancer

6 Survival results of PSMA/PET-based salvage radiotherapy for recurrent prostate cancer

Saved in:

Bibliographic Details
Main Authors:	N. Grivas, P. van Leeuwen, E. Wit, A. Vis, J. Nieuwenhuijzen, F. Pos, H. van der Poel
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168325000370
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biochemical failure-free survival of 18F-rhPSMA-7 and 18F-flotufolastat PET-guided salvage radiotherapy for patients with recurrent prostate cancer
by: Marco M. E. Vogel, et al.
Published: (2025-01-01)

Incidental Discovery of Hepatocellular Carcinoma on 18F-PSMA PET CT Performed for Prostate Cancer Reassessment
by: Lauren Hekman, et al.
Published: (2023-01-01)

B-CLL with negative 18F-FDG PET/CT and intensive solitary lesion on PSMA PET/CT mimicking prostate cancer bone metastases
by: Theresa Jung, et al.
Published: (2025-01-01)

Which PSMA PET/CT interpretation criteria most effectively diagnose prostate cancer? a retrospective cohort study
by: Le Ma, et al.
Published: (2025-01-01)

Extended Salvage Pelvic Lymph Node Dissection in Patients with Recurrent Prostate Cancer
by: Daniar K. Osmonov, et al.
Published: (2014-01-01)

Gastric Adenocarcinoma Incidentally Detected by PET/CT with PSMA Ligands
by: Cesare Michele Iacovitti, et al.
Published: (2025-01-01)

Salvage radiofrequency ablation followed by external beam radiotherapy for inoperable recurrent differentiated thyroid cancer
by: Chung-Shih Chen, et al.
Published: (2024-12-01)

Radiotherapy for Oligometastases and Oligo-Recurrence of Bone in Prostate Cancer
by: Ken-ichi Tabata, et al.
Published: (2012-01-01)

The PROMISE-V2 PRIMARY score and SULmax [18F]PSMA-1007 PET/CT in primary staging of prostate cancer
by: J. Antonio Serna-Macias, et al.
Published: (2024-10-01)

Evaluating [<sup>68</sup>Ga]-Ga PSMA PET/CT for Detecting Prostate Cancer Recurrence Post-High-Intensity Focused Ultrasound and Brachytherapy: A Single-Center Retrospective Study
by: Andrea Di Giorgio, et al.
Published: (2024-12-01)

Salvage Brachytherapy for Castration-Resistant and External Beam Radiotherapy-Resistant Local Recurrence 17 Years after Radical Prostatectomy
by: Shogo Hosogoe, et al.
Published: (2015-01-01)

Survival in Ecuadorian Patients with Prostate Cancer Clinically Treated with Radiotherapy and Chemotherapy
by: Alberto Sánchez Garrido, et al.
Published: (2024-01-01)

First Report of Two Cases of Acute Gastric Ischemia after Robot-Assisted Radical Cystectomy
by: Nikolaos Grivas, et al.
Published: (2021-01-01)

Diagnostic accuracy of 18F Prostate Specific Membrane Antigen (PSMA) PET-CT radiotracers in staging and restaging of high-risk prostate cancer patients and patients with biochemical recurrence: protocol for an overview of reviews [version 2; peer review: 2 approved]
by: Susan Ahern, et al.
Published: (2025-01-01)

PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy
by: Vineet Mohan MSc, et al.
Published: (2020-07-01)

Relating proton LETd to biological response of parotid and submandibular glands using PSMA-PET in clinical patients
by: Dirk Wagenaar, et al.
Published: (2025-05-01)

18 The role of PSMA expression in predicting aggressive disease phenotypes in patients with prostate cancer
by: G. Gandaglia, et al.
Published: (2025-01-01)

Do you know your PSMA-tracer? Variability in the biodistribution of different PSMA ligands and its potential impact on defining PSMA-positivity prior to PSMA-targeted therapy
by: Jan Heilinger, et al.
Published: (2025-01-01)

The impact of preliminary patient hydration on physiological [18F]PSMA-1007 uptake in the urinary bladder on PET/CT
by: T. L. Antonevskaya, et al.
Published: (2024-06-01)

Scatter Artifact with Ga-68-PSMA-11 PET: Severity Reduced With Furosemide Diuresis and Improved Scatter Correction
by: Courtney Lawhn-Heath MD, et al.
Published: (2018-11-01)

Incidental discovery of gastrointestinal stromal tumor via PSMA-PET/CT imaging: Insights from a case report
by: Venetia A. Florou, et al.
Published: (2025-01-01)

Dose-volume parameter evaluation of a sub-fractionation workflow for adaptive radiotherapy of prostate cancer patients on a 1.5 T magnetic resonance imaging radiotherapy system
by: Georgios Tsekas, et al.
Published: (2025-01-01)

Real world experience with [99mTc]Tc-HYNIC-iPSMA SPECT prostate cancer detection: interim results from the global NOBLE registry
by: Pete Tually, et al.
Published: (2024-12-01)

Clinical Results after High-Dose Intensity-Modulated Radiotherapy for High-Risk Prostate Cancer
by: Valérie Fonteyne, et al.
Published: (2012-01-01)

5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
by: Andrew Thamboo, et al.
Published: (2021-02-01)

Development of Novel Nomograms to Predict 5- and 7-Year Biochemical-Recurrence-Free Survival in High-Risk Prostate Cancer Patients After Carbon-Ion Radiotherapy and Androgen Deprivation Therapy
by: Takanobu Utsumi, et al.
Published: (2025-01-01)

Hypofractionated External-Beam Radiotherapy for Prostate Cancer
by: L. Chinsoo Cho, et al.
Published: (2013-01-01)

Robotic-Assisted Laparoscopic “Salvage” Rectopexy for Recurrent Ileoanal J-Pouch Prolapse
by: Madhu Ragupathi, et al.
Published: (2010-01-01)

Role of 18F-PSMA-1007 PET/CT-derived quantitative volumetric tumor parameters in cytoreductive radical prostatectomy selection for patients with low-volume metastatic hormone-sensitive prostate cancer: a retrospective study
by: Junjie Fan, et al.
Published: (2025-02-01)

PSMA antibody, humanized PSMA.CAR10.3, or Cetuximab increases prostate cancer localization of NF-κB p50-deficient immature myeloid cells (p50-IMC) and phagocytosis by their macrophage progeny
by: Mohammad A. Alzubi, et al.
Published: (2025-02-01)

Radioterapia guiada por PET-PSMA en cáncer de próstata: experiencia en el escenario curativo y en el salvamento
by: Juan C. Galvis, et al.
Published: (2023-04-01)

Imply on diagnosis and early prognosis of preoperative [68Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin
by: K. Pełka, et al.
Published: (2025-01-01)

Salvage transoral laser microsurgery for early local recurrence of glottic squamous cell cancer
by: Zhimou Cai, et al.
Published: (2023-05-01)

Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer
by: Mikael Anttinen, et al.
Published: (2025-01-01)

MR-Guided Adaptive Radiotherapy in Localized Prostate Cancer
by: Andrea Gaetano Allegra MD, et al.
Published: (2025-01-01)

No impairment of quality of life after radiotherapy for prostate cancer
by: Maria M. Meier, et al.
Published: (2024-12-01)

Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
by: Emiel A. De Jaeghere, et al.
Published: (2022-08-01)

PSMA Theranostics: Current Status and Future Directions
by: Kambiz Rahbar MD, et al.
Published: (2018-06-01)

Retrospective Analysis of the Factors Affecting Recurrence, Survival, and Effect of Hippocampus Radiotherapy Doses on Neurocognitive Functions in Patients Diagnosed with Glioblastoma Multiforme
by: Sevilcan İnan, et al.
Published: (2024-04-01)

Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study
by: Emiel A. De Jaeghere, et al.
Published: (2024-12-01)